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Abs tract
The objective of this study was to determine the sensitivity of tartrate-resistant acid phosphatase (Bone TRAP-5b) for early 
detection of bone metastases (BM) and to investigate the efficacy of bisphosphonates (BF) (zolendronic acid-ZA) in prevention of 
bone metastases in patients with Renal Cell Carcinoma (RCC). The 60 patients with RCC with proven BM were investigated to assess 
the sensitivity and specificity of Bone TRAP-5b. 95 patients with RCC with high level of tartrate-resistant acid phosphatase (Bone 
TRAP-5b) (8,5±0,2 IU/L) after radical surgical treatment were divided into two groups: 1-st group: (n=44) received zolendronic acid 
(ZA) (BF+), and 2-nd group (n=51) patients didn’t receive ZA (BF–). Patients of both subgroups were similar by age, sex, stage of 
disease. The levels of Bone TRAP-5b, Ca++, alkaline phosphatase, LDG were accessed every 3 months, and MRI imaging, bone 
scan with 99mTc every 6 month in both groups. We determined the high correlation between bone TRAP-5b and the presence of bone 
metastases (r=0,9; p <0,05), but its level wasn’t dependent with the number of BM. The results showed the high sensitivity and spec-
ificity of Bone TRAP-5b at the critical value of 5.2 IU/L (98,3 % and 90,0 %), (χ2=64,6; p<0.01). Using BF for the prevention of bone 
metastases in high risk group patients with RCC provides a significant difference in the incidence of bone metastases in patients. 
Keywords: tartrate-resistant acid phosphatase-5b, renal cell cancer (RCC), bone metastases, bisphosphonates, zolendronic 
acid, serum level.
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1. Introduction
The metastatic tumors of musculoskeletal system are more prevalent than the primary, 
and take up to 96 % of all tumors of skeletal system [1]. Bone metastases are usually diagnosed 
in 30–50 % of cases of RCC and take the third place in frequency after lung and liver metastases. 
In 48 % of patients RCC is diagnosed because of BM presence [2]. Usually BM are localized in the 
vertebrae in 40–50 % cases, long bones in 30–40 % cases and pelvic bones in 20–30 % of all cases, 
beside femoral bone destruction occurs in 45–60 % of cases [3]. 
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The BM significantly complicates the course of the disease, impairs the quality of life of 
patients due to the presence of severe pain, pathological fractures of the bones, significant limb 
dysfunction, the risk of hypercalcemia and spinal cord compression [4]. 
Diagnosis of BM is based both on the results of clinical and radiological methods of investi-
gations. Both computer tomography (CT) and MRI can reveal the nature of bone structure changes, 
the prevalence of tumor components, their location, but despite the high informative properties of 
these modern methods of examination it can detect the tumor lesions when bone demineralization 
reaches 30–40 %, rather late stages of the disease [5]. 
The importance of detecting, identifying bone resorption markers is essential for prognosis 
of treatment effectiveness, the duration of disease-free period and overall survival of the patients 
[6]. The intensive search for possible biological markers of the bone resorption as predictors of bone 
metastases in patients with RCC has been carried out in recent years.
The main biochemical markers, usually used as indicators of bone resorption are products 
of degradation of collagen I and II types, N- and C-telopeptides, tartrate-resistant acid phosphatase 
(bone TRAP 5B), pyridinolin and deoxypyridinoline [7]. 
Many reports has been presented in recent years about detecting of products of degradation 
types 1 and 2 collagen, N- and C-telopeptides in patients with bone metastases at prostate and 
breast cancer, thyroid cancer as indicators of BM, especially during treatment with bisphospho-
nates [8]. 
Acid phosphatases are widely distributed enzymes from the class of hydrolases and mani-
fested their properties to phosphorus monoetheres of orthophosphate in acidic area. It differs from 
other lysoforms with the resistance to the tartrate’s inhibitory action, released from osteoclasts 
during resorption, participates in the destruction of extracellular matrix and excreted into the blood 
serum in right proportion regarding to the intensity of resorption processes [9]. The high activity of 
serum TRAP-5b reflects an increasing of intensity of bone resorption [9]. The scientific literature 
describes changes in the serum concentration of bone-TRAP-5b with metastatic bone lesions in pa-
tients with prostate, breast cancer, multiple myeloma, lung cancer with a sensitivity and specificity 
level from 85 to 95 % [10]. 
The high sensitivity and specificity of TRAP-5b as a predictor of bone lesions in patients 
during treatment with bisphosphonates was reported ranging from 71 to 90 % [11]. 
2. Aim of research
To determine the sensitivity of tartrate-resistant acid phosphatase (bone TRAP-5b) for early 
detection of bone metastases and to investigate the efficacy of bisphosphonates (ZA) in prevention 
of BM in patients with RCC and high risk of bone metastases.
3. Materials and methods
The bone-TRAP 5b activity was determined in patients with RCC which were divided into 
two groups: 1-st 60 patients with RCC with clinical and radiologically proven BM and 2-nd – 95 pa-
tients with RCC after surgical treatment with elevated level of tartrate-resistant acid phosphatase 
(Bone TRAP-5b) (8,5±0,2 IU/L) (Table 1), as the high risk of bone metastases.
Osteolytic metastases were detected in 39 (65 %) patients, osteoblastic – in 9 (15 %) patients, 
mixed lesions – in 12 (20 %) cases. In this group of patients, at least 1 skeletal event was registered 
in 18 (30,0 %) patients, two in 31 (51,7 %) cases and in 11 (18,3 %) more than 3 skeletal events were 
registered. Combined treatment including operative was performed in 42 (70.0 %) of patients with 
BM, conservative – 18 (30.0 %) of cases.
Patients from 2-nd group were divided into two groups: 1-st group: (n=44) (46.32 %) were 
treated with ZA (BF +), and 2-nd group (n=51) patients (53.68 %) did not receive ZA (BF–). Patients 
of both subgroups were similar by age, sex, stage of disease (Table 2). 
Patients of 1-st subgroup of the main group (44 subjects) received adjuvant immunothera-
py (IFN) and bisphosphonates and patients of the 2nd subgroup from the main group (51 individu-
als), received only adjuvant immunotherapy. The control group consists of 25 volunteers with RCC 
with normal ranges of TRAP-5b, treated with adjuvant immunotherapy. 
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Table 1
Patient’s characteristic with bone metastases of Renal Cell Carcinoma
Data Patients with BM n=60 (%) Patients without BM n=95 (%)
Sex
Men 45 (75,0) 62 (51,7)
Women 15 (25,0) 58 (48,3)
Mean age, y.o 56,3±1,3 55,1±1,1
Tumor stage
T1b 2 (3,3) 6 (5,0)
Т1а 14 (23,3) 32 (26.7)
Т2а 12 (20,0) 23 (19,2)
Т2b 10 (16,7) 20 (16,7)
Т3а 12 (20,0) 19 (15,8)
Т3b 7 (11,0) 10 (8,3)
Т4 3 (5,0) 11 (9,2)
Histologic gradation
G2 6 (10,0) 59 (49,2)
G3 39 (65,0) 51 (42,5)
G4 15 (25,0) 10 (8,3)
Lymphatic nodes
N0 38 (64,1) 80 (67,0)
N1 19 (32,0) 29 (25,0)
N2 3 (5,1) 11 (8,0)
Lung metastases 23 (38,3) 0
Other organs 10 (16,7) 0
Table 2
Patient’s characteristic without bone metastases of Renal Cell Carcinoma
Data 1-st group BF (+) (n=44) 2-nd group BF (–) (n=51)
Sex
Men 23 (52,2) 24 (47,0)
Women 21 (47,7) 27 (52,9)
Mean age, y.o 53,1±1,9 56,1±1,6
Tumor stage
I 13 (29,5) 13 (25,5)
II 18 (40,9) 17 (33,3)
III 12 (27,2) 20 (39,2)
IV 1 (2,3) 1(1,9)
Morphology, Fuhrman’s criteria, n (%)
II 23 (52,3) 25 (49,0)
III–IV 21 (47,7) 26 (50,9)
Bone TRAP 5b IU/l 7,3±0,3 6,5±0,2
Alkaline Phosphatase, U/l 1564,74±66,6 1827,9±217,3
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Observational period, months 18,5±0,7 14,6±0,6
Zolendronic acid was administered at dose 4 mg intravenously monthly (every 28 days) un-
der the control of tartrate-resistant acid phosphatase every three months, within 6 months after the 
normalization of bone TRAP 5b BF was discontinued. 
The levels of alkaline phosphatase (U/L), serum calcium (mmol/l), lactate dehydroge-
nase (U/l) were accessed using modern, generally accepted methods in the biochemical and immu-
nological laboratories of the National cancer institute; 
 The quantitative determination of TRAP-5b active isoform in serum samples was per-
formed by immunoassay (ELISA) method with monoclonal antibodies specific for TRAP-5b os-
teoclasts according to the Bone TRAP® Assay kit, SB-TR 201A series, production USA. The 
measurement wavelength was 405 nm, measuring range – 0,5–10 units/l, sensitivity – 0,5 units/l. 
All biochemical values were accessed every 3 months. The CT and MRI imaging, bone scan 
with 99mTc were performed every 6 months. 
4. Results
As shown in Table 3 the levels of alkaline phosphatase (APh), serum calcium (Ca++) and 
lactate dehydrogenase (LDH) concentrations didn’t differ significantly in different groups (p> 0.05). 
The TRAP-5b serum level varied from 5.3 to 16.2 units/l in the first group and from 3.5 
to 10.2 IU/l in the second group. It was noticed that the bone TRAP-5b concentration in pa-
tients of 1-st group (9.8±0.3) IU/l on average was significantly higher than in patients of the 
second group – (6.1±0.1) units/l and with practically healthy subjects of the control group – 
(2.9±0.3) IU/l on average p <0.05 (Table 3).
Table 3
Biochemical Markers of Bone Turnover
Marker
Patients
Control group (n=20)
I-st group with BM (n=60) 2 nd group without BM (n=95)
BoneTRAP-5b IU/l 9,8±0,2* 6,1±0,1* 2,9±0,3
Alcaline Phosphatase U/l 1890,6±100,3 1651,01±97,6 1458,6±88,3
Ca ++ mmol/l 2,3±0,01 2,3±0,01 2,3±0,03
LDG U/l 608,7±29,1 430,1±18,8 423,5±37,7
Observation, months 18,5±0,7 14,6±0,6 18,4±1,2
Note: * – p<0,05 with CG 
Despite the absence of skeletal metastatic lesion in patients of the second group, the bone 
TRAP-5b concentration was also significantly higher comparing with control group (p≤0.05).
The maximum sensitivity and specificity of Bone TRAP-5b we determined at value of 
5.2 IU/L (98,3 % and 90,0 %), (χ2=64,6; p<0.01). When the concentration increased up to 9.8 IU/l, 
the sensitivity decreased to 26,7 % (χ2=6,6; p=0.01). We determined high correlation between levels 
of boneTRAP-5b and presence of bone metastases (r=0,9; p <0,05), but its level didn’t dependent 
with the number of BM. There was no correlation of alkaline phosphatase, LDH with the presence 
of bone lesions (r=0,19; p<0,05) (Table 4). 
The mean level of TRAP-5b was elevated to 8,5±0,2 IU/l in all patients. The average pe-
riod of follow-up was 18.5 months. During the treatment period in patients of 1st subgroup (BF+) 
we received the marked tendency to normalization of bone TRAP-5b from (7,3±0,7) IU/L to 
(5,7±0,6) IU/l after 18 months. 
In patients of 2nd subgroup (BF–) we observed the increase of bone TRAP-5b from 
(6,40±0,4) IU/L, (8,3±0,4 ) IU/l, (8,1±0,3) IU/l, on average by 6, 9 and 18 months follow-up respec-
tively (Fig. 1). 
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Table 4
The Sensitivity and Specificity of Вone TRAP-5b
Critical value The Sensitivity, % (95 % CІ ) The Specificity, % (95 % CІ) χ2 P
5,2 98,3 (92,9–99,9)
90,0 
(73,8–94,7) 64,6 <0,01
6,1 93,3 (87,3–96,0)
90,1 
(72,0–98,0) 52,2 <0,01
7,1 76,7 (70,0–79,4)
90,0 
(70,1–98,2) 27,7 <0,01
9,8 26,7 (21,0–26,7)
99,8 
(83,0–100,0) 6,6 =0,01
 
 
  
* * 
*
bone TRAP-5b, IU/l 
Fig. 1. The ВoneTRAP-5b dynamics during the treatment with ZA every 4 week regimen (IU/l)
The significant difference was observed in the incidence of BM in patients of (BF+) and 
(BF–) groups (20.5 and 54.9 %) respectively, χ2=11,78; p <0.05; but time of appearance of BM in 
patients did not differ between the two subgroups (7,8±0,9) and (7,8±0,4) months (Fig. 2).
 
Fig. 2. Frequency of appearance of bone metastases in patients during the treatment 
with BF 
 
5. Discussion 
The metastatic lesions of a skeleton become a serious problem of the modern 
oncology. Nearly in one-third part of patients the RCC is usually diagnosed with 
synchronous metastatic process and in 20 % progression of the disease occurs one 
month after nephrectomy, according to our results, kidney cancer was diagnosed 
simultaneously with bone metastases in 23.3 % of patients [12]. 
The main goal of the treatment strategy of these patients is increasing of life 
expectancy, because the average survival rate for patients with RCC with multiple 
BM is 12 months, where 50 % of patients dying within 10 months and only 10 % of 
patients have five years survival rate [12].  
The surgical treatment is mainly performed with symptomatic aim to decrease 
and to prevent complications, associated with the destruction of bone tissue. In 
patients with BM we have diagnosed multiple bone lesions three times more often 
than in the case of a solitary cancer – 73.0 % and 27.0 % respectively, moreover, in 
most of them, there was a pathological fracture (44.0 %), and it’s threat was 
diagnosed in 27.0 % of patients.  
The scientific interest to bone resorption markers in patients with RCC has been 
increased in recent years [9]. Numerous studies were devoted to the influence of 
metastatic cells on the bone tissue and searching for biochemical markers of its 
destruction. Ozu C. et al. [13] argue that the alkaline phosphatase and bone TRAP-5b 
have a high ability to detect early bone lesions of patients with breast cancer - in 
almost 70 % of cases.  
Smith M. et al. [14] in the study with 1,468 patients with prostate cancer 
demonstrated the reliable effectiveness of an increased concentration of bone TRAP-
5b in the early diagnosis of BM and its effectiveness on bisphosphonates treatment.  
Our results obtain a close correlation between elevated levels of TRAP-5b and 
the presence of metastatic lesions (r=0.9; p <0.05), without dependence of its level on 
the number of bone lesions.  
% 
P<0.05 
Fig. 2. Frequency of appearance of b ne metastases in patients during the treatment wi h BF
5. Discussion
The metastatic lesions of a skeleton become a serious problem of the modern oncology. 
Nearly in one-third part of patients the RCC is usually diagnosed with synchronous metastatic 
process and in 20 % progression of the disease occurs one month after nephrectomy, according 
to our results, kidney cancer was diagnosed simultaneously with bone metastases in 23.3 % of 
patients [12].
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The main goal of the treatment strategy of these patients is increasing of life expectancy, 
because the average survival rate for patients with RCC with multiple BM is 12 months, where 
50 % of patients dying within 10 months and only 10 % of patients have five years survival rate [12]. 
The surgical treatment is mainly performed with symptomatic aim to decrease and to pre-
vent complications, associated with the destruction of bone tissue. In patients with BM we have di-
agnosed multiple bone lesions three times more often than in the case of a solitary cancer – 73.0 % 
and 27.0 % respectively, moreover, in most of them, there was a pathological fracture (44.0 %), and 
it’s threat was diagnosed in 27.0 % of patients. 
The scientific interest to bone resorption markers in patients with RCC has been increased 
in recent years [9]. Numerous studies were devoted to the influence of metastatic cells on the bone 
tissue and searching for biochemical markers of its destruction. Ozu C. et al. [13] argue that the 
alkaline phosphatase and bone TRAP-5b have a high ability to detect early bone lesions of patients 
with breast cancer – in almost 70 % of cases. 
Smith M. et al. [14] in the study with 1,468 patients with prostate cancer demonstrated the 
reliable effectiveness of an increased concentration of bone TRAP-5b in the early diagnosis of BM 
and its effectiveness on bisphosphonates treatment. 
Our results obtain a close correlation between elevated levels of TRAP-5b and the presence 
of metastatic lesions (r=0.9; p <0.05), without dependence of its level on the number of bone lesions. 
We investigated the sensitivity and specificity of the marker at its various critical values and 
the optimum value of Bone TRAP-5b level was determined at 5.2 units/l. It has been shown that 
the sensitivity of the marker has decreased from 98.3 % (95 % CI (92.9–99.9) to 26.7 % (95 % CI 
(21.0–26.7), with its lowest value established at the bone TRAP concentration at 9.8 units / l, the 
specificity of the marker remained at 90 (95 % CI (73.8–94.7) – up to 99 % (95 % CI (85–100 %).
However, in his observations, R. Preussner (2014) found out that the sensitivity and spec-
ificity of TRAP-5b in patients with RCC was ambiguous: the sensitivity of marker was reduced 
to 47 % with a critical marker level rising from 5 units/l to 50 units/l, but the specificity elevated 
from 36.7 to 96.7 % [9]. 
Korpela J. et al. (2006) provided a study that illustrates the significant growth of TRAP-5b 
with the presence of bone metastases in patients with breast carcinoma, with the results confirm-
ing a sensitivity of 87 % and a specificity of 62 % at a bone TRAP-5b serum level of 3.65 units/l 
[15]. According to Yao N. S., the diagnostic value of TRAP-5b with a sensitivity of 63.9 % and 
a specificity of 76.8 % is important in patients with small cell lung cancer at a concentration of 
2.55 units/l [16].
Thus our results coincide with the literature data, as we have shown a significant increase of 
TRAP-5b serum level in patients with bone metastases, comparing to the other group. 
Thus taking into account the presence of pathological resorption of bone tissue bisphospho-
nates (BF) have a key role in the treatment and prevention of possible skeletal events [17].
Zaghloul M.S., Boutrus R. (2010) demonstrated 12-month survival increase in patients with 
BM of bladder cancer within the treatment with zolendronic acid [18].
In our study, the main group of patients (with a serum level of boneTRAP-5b more than 
5.2 units/l) 3 months later the introduction of zolendronic acid the bone TRAP -5b decrease was to 
9 % comparing with the baseline, and at the end of the study it was (5.7±0.6) IU/l. In the second sub-
group of patients, received adjuvant therapy only, bone TRAP-5b was (7.0±0.3) IU/L and (8.1±0.4) 
at 6 and 18 months respectively (p=0.03).
It should be noted that patients of main group who had experienced BM in the future the 
average level of TRAP-5b was increased to 29 % comparing with the control group nearly 6 months 
before their radiological confirmation (8.7±0,7) IU/l and (6.8±0.3) IU/l.
Consequently, the obtained data show the high diagnostic sensitivity and specificity of 
TRAP-5b as a marker of metastatic skeletal defeat in patients with RCC. 
The determination of the level of this marker in patients with RCC provides the opportunity 
to determine the risk group of patients with the possible development of skeletal lesions, which in 
general determines the patient’s survival [19]. 
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The high sensitivity of the marker can increase the accuracy of the early preclinical diag-
nosis of skeletal metastasis, assessing the degree of metastatic process, as well as monitoring the 
effectiveness with BF treatment [20].
The study shows promising feasibility in finding and developing adequate methods for pre-
dicting the onset of BM in patients with RCC, as well as in treatment monitoring.
6. Conclusions
1. The diagnostic sensitivity and specificity of bone TRAP-5b as a marker of metastatic 
lesions was proven in patients with skeletal lesions in RCC at its various meanings: the highest 
sensitivity and specificity levels obtained by bone TRAR-5b level (5,1–5,3) IU /l (98,3 and 90.0 % 
respectively). When boneTRAP-5b level was 7,1 IU/l sensitivity was 76.7 %; (95 % CI (70,0–79,4)) 
and specificity was 90.0 %; (95 % CI (70,1–98,2)); χ2=27,7; p <0.01.
2. The mean critical value of bone TRAP-5b was (5,2 IU/l) with a high probability of bone 
lesions appearance in patients with RCC after the radical surgery of the primary tumor. 
3. There was a significant difference in the incidence of bone metastases in patients with (1st 
subgroups (BF+) and 2nd subgroup (BF–) – 20.5 and 54.9 % respectively; p <0.05). 
4. The administration of 4 mg of zolendronic acid in q4 week regimen in patients with ele-
vated levels of bone TRAP-5b leads to normalization of its serum level within 18 months. 
5. The ZA administration in patients with RCC with the high risk of bone lesions provides a 
significant difference in the incidence of bone metastases in patients with (1st subgroups (BF+) and 
2nd subgroup ( BF–) – 20.5 and 54.9 % respectively; p <0.05).
6. BF can prevent and reduce the risk of skeletal lesions and improve patient’s outcomes.
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